Major Depression in the Primary Care Setting: Updates for Relapse Prevention and Sustained Recovery- Identify residual symptoms of MDD and evaluate their impact on symptomatic remission and recovery.
Review recent clinical updates on traditional and newer pharmacotherapies for Major Depressive Disorder (MDD) and their benefits/limitations in symptomatic remission and recovery.
Examine the role of serotonin in the pathogenesis of MDD, including the significance of molecular targets in mitigating residual symptoms of depression.
1.25 Free AANP CEUs which includes 0.62 Free Hours of Pharmacology
Expires 6/5/15
Supported by an educational grant from Takeda Pharmaceuticals International, Inc., U.S. Region, and Lundbeck Pharmaceutical Services, LLC